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Background: Porcine reproductive and respiratory syndrome (PRRS) is characterized by severe reproductive failure
and severe pneumonia in neonatal pigs and is caused by PRRS virus (PRRSV). Glycoprotein 5 (GP5) from PRRSV is a
key inducer of neutralizing antibodies. Flagellin, a toll-like receptor 5 (TLR-5) agonist, is an effective inducer of innate
immune responses. This study presents a novel PRRSV vaccine candidate based on the adjuvant effect of Salmonella
Typhimurium FljB fused with PRRSV GP5.
Results: A truncated rGP5 gene lacking the signal peptide and transmembrane sequences was amplified and
inserted into prokaryotic expression vectors, pColdI or pGEX-6p-1. Salmonella Typhimurium flagellin fljB was
amplified and inserted into the plasmid pCold-rGP5, generating recombinant plasmid pCold-rGP5-fljB. Histidine
(His)-tagged rGP5 and fusion protein rGP5-FljB were induced with isopropyl-β-d-thiogalactoside, verified by
SDS-PAGE and western blotting, and purified via Ni-NTA affinity columns. The TLR-5-specific bioactivity of fusion
protein rGP5-FljB was determined by detecting the expression levels of the cytokine IL-8 in HEK293-mTLR5 cells
by sandwich ELISA. The purified endotoxin-free proteins were administered intraperitoneally in a C3H/HeJ
mouse model. The results show that immunization with the fusion protein rGP5-FljB induced a significantly
enhanced GP5-specific and PRRSV-specific IgG response that persisted for almost 5 weeks. Co-administration of
the rGP5 with R848 or Alum also yielded a higher IgG response than administration of rGP5 alone. The IgG1/IgG2a
ratio in the rGP5-FljB immunization group was significantly higher (9-fold) than that in the rGP5 alone group and was
equivalent to the response in the rGP5 + Alum immunization group, suggesting a strong Th2 immune response was
induced by the fusion protein.
Conclusions: Purified fusion protein rGP5-FljB is capable of activating the innate immune response, as demonstrated
by the results of our TLR-5-specific bioactivity assay, and FljB has adjuvant activity, as shown by the results from our
administration of rGP5-FljB in a mouse model. Our findings confirm that FljB could serve as an excellent adjuvant for
the production of GP5-specific and PRRSV-specific IgG antibodies as part of an induction of a robust humoral immune
response.
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Porcine reproductive and respiratory syndrome (PRRS)
has been recognized as one of the most serious infec-
tious diseases of swine since its first appearance in North
America in 1987 [1]. The disease is characterized by
severe reproductive failure and severe pneumonia in
neonatal pigs and is caused by PRRS virus (PRRSV),
a member of the Arteriviridae family, order Nidoviri-
dales [2].
Pigs mount a rapid antibody response to infection by
PRRSV, but the antibodies are mainly directed to the
N- and M-proteins and are non-neutralizing [3]. The
primary neutralization epitope of some North American
PRRSVs is located in the middle of the glycoprotein 5
(GP5) ectodomain [4]. A truncated GP5 without the signal
peptide sequence or the predicted transmembrane regions
(residues 60–130) is able to elicit protective antibodies
capable of detecting PRRSV-infected cells and of distin-
guishing this virus from others [5]. Currently, killed-virus
and modified-live PRRSV vaccines are used to control
PRRS. However, both of these types of vaccines have in-
herent drawbacks and the development of novel PRRSV
vaccines is urgently needed [6, 7].
Recent advances in innate immunity research have
indicated that pathogen-associated molecular patterns
(PAMPs) are promising molecular adjuvants for subunit
vaccines [8, 9]. Flagellin, the structural component of
the flagellar filament in various locomotive bacteria, is a
ligand for toll-like receptor 5 (TLR-5) in host cells [10,
11]. An increasing number of studies have demonstrated
the effectiveness of flagellin as an adjuvant [12, 13], and
flagellin is an effective inducer of innate immune effec-
tors, such as cytokines and nitric oxide, thereby stimu-
lating the activation of adaptive immune responses [14].
In the present study, we cloned a truncated rGP5 gene
and constructed the fusion protein rGP5-FljB using a
prokaryotic system. We then determined the TLR-5-
specific bioactivity of fusion protein rGP5-FljB by detect-
ing the expression levels of the cytokine interleukin 8
(IL-8) in HEK293-mTLR5 cells by sandwich enzyme-
linked immunosorbent assay (ELISA). Last, we assessed
the immunogenicity of rGP5 and the adjuvant properties
of FljB in a mouse immunization assay. ELISA-based de-
tection of GP5-specific and PRRSV-specific antibodies
suggested that FljB could enhance the immunogenicity
of GP5 and induce a robust humoral immune response,
thus providing more effective antibodies against PRRSV.
Results
Construction of expression plasmids bearing rGP5 and
rGP5-fljB
A truncated rGP5 gene lacking the signal peptide se-
quence and transmembrane regions was amplified using
a linker-based overlap-PCR strategy. The gene of interestwas inserted into the expression plasmids pColdI and
pGEX-6p-1 to add a His or GST tag, respectively. Re-
combinant plasmid pCold-rGP5-fljB was constructed by
using enzymes to digest the plasmid pCold-rGP5 and
inserting the PCR product fljB (Fig. 1). The DNA sequen-
cing results indicated that the sequences of the inserts
were identical to the template sequences.
Expression and purification of rGP5 and rGP5-FljB proteins
The expression of His-rGP5, GST-rGP5, and rGP5-FljB
was induced by addition of IPTG to the culture medium.
SDS-PAGE results indicated that the molecular weights
of the tagged proteins were about 15 kDa for His-rGP5,
40 kDa for GST-rGP5, and 67 kDa for rGP5-FljB, as ex-
pected (Fig. 2). His-rGP5 and rGP5-FljB were purified
via a Ni-NTA affinity column and verified by SDS-PAGE
analysis (Fig. 3).
Immunoblotting
To analyze the immunoreactivity of the rGP5 and fusion
protein rGP5-FljB, polyclonal antibodies against PRRSV
or FljB were used as the primary antibodies in a western
blotting assay. The results showed that the bacterially-
expressed rGP5 and rGP5-FljB were able to react with
the PRRSV-specific antibody (Fig. 4a). Additionally, western
blotting with anti-FljB antibodies confirmed the presence
of a highly purified 67 kDa protein corresponding to
rGP5-FljB (Fig. 4b).
TLR-5 activation by purified fusion protein rGP5-FljB
After removal of endotoxin from the purified proteins
rGP5 and rGP5-FljB, very low endotoxin levels, less than
0.03 EU/μg, were detected in the protein preparations,
indicating that LPS contamination in the prepared pro-
teins was negligible. To verify the activation of innate
immune signaling by fusion protein rGP5-FljB, we con-
ducted a TLR-5-specific bioactivity assay. Stimulation
with rGP5-FljB at several different protein concentra-
tions elicited a robust production of IL-8 that was sig-
nificantly higher than that elicited by stimulation with
similar concentrations of rGP5 alone (p < 0.01; Fig. 5).
The observed up-regulation of chemokine IL-8 following
stimulation with rGP5-FljB suggested that the prepared
endotoxin-free rGP5-FljB was able to activate the innate
immune response in vitro.
Effects of rGP5-FljB treatment on GP5-specific and
PRRSV-specific serum antibodies
To examine the antibody response to the recombinant
protein in an animal model, we administered the
endotoxin-free fusion protein rGP5-FljB via an intraper-
itoneal injection. The results showed that immunization
with the fusion protein induced a significantly enhanced
GP5-specific and PRRSV-specific IgG response after
Fig. 1 Schematic representation for the construction of rGP5 and rGP5-fljB. rGP5 fragment with the deletion of its signal peptide (green) and
transmembrane regions (light grey) was amplified by overlap-PCR, and inserted into the BamHI and EcoRI digested expression vector pColdI or
pGEX-6p-1 to create pCold-rGP5 or pGEX-6p-1-rGP5 respectively. Flagellin fljB gene (light blue) was amplified from the genomic DNA of attenuated
Salmonella Typhimurium SL7207 strain and cloned into the EcoRI and SalI sites of pCold-rGP5, resulting in a recombinant plasmid pCold-rGP5-fljB.
“L” represents the linker sequence GGGGS
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rGP5 alone (Figs. 6b and 7). The titer in the rGP5-FljB
immunization group was elevated almost four-fold after
the third immunization compared with the titer after the
second immunization. Co-administration of the rGP5 with
R848 or Alum also yielded a higher IgG response than
immunization with rGP5 alone (Fig. 6b).
Immune subtype induced by fusion protein rGP5-FljB
We investigated the subtype of the immune response
after three immunizations with fusion protein rGP5-
FljB by detecting serum IgG1 and IgG2a via indirectFig. 2 SDS-PAGE analysis of recombinant bacteria of BL21 (DE3)(pCold-rGP5)
(c). (a) Lanes: M, molecular weight markers; 1, product of BL21(DE3)(pCold) ind
by IPTG; 3, Inclusion bodies of bacteria bearing His-rGP5 induced by IPTG; 4, p
weight markers; 1, product of BL21(DE3)(pGEX-6p-1) induced by IPTG; 2, Lysat
bodies of bacteria bearing GST-rGP5 induced by IPTG. (c) Lanes: M, molecular
product of bacteria bearing rGP5-FljB not induced; 3, Lysate supernatant of ba
bearing rGP5-FljB induced by IPTGELISA. Co-administration of rGP5 with R848 or
Alum induced a robust Th2 immune response. The
IgG1/IgG2a ratio in the group of mice immunized
with rGP5 alone was 4.0, whereas in the group of
mice immunized with rGP5 together with R848 or
Alum this ratio was 11.8 or 35.5, respectively. The
IgG1/IgG2a ratio in the rGP5-FljB immunization
group was significantly higher (9-fold) than that in
the rGP5 alone immunization group, and reached a
level equivalent to the IgG1/IgG2a ratio in the rGP5
+ Alum immunization group (Fig. 6c), suggesting a
strong Th2 immune response.(a), BL21(DE3)(pGEX-6p-1-rGP5) (b) and BL21 (DE3)(pCold-rGP5-fljB)
uced by IPTG; 2, Lysate supernatant of bacteria bearing His-rGP5 induced
roduct of bacteria bearing His-rGP5 not induced. (b) Lanes: M, molecular
e supernatant of bacteria bearing GST-rGP5 induced by IPTG; 3, Inclusion
weight markers; 1, product of BL21(DE3)(pCold) induced by IPTG; 2,
cteria bearing rGP5-FljB induced by IPTG; 4, Inclusion bodies of bacteria
Fig. 3 SDS-PAGE analysis of purified His-rGP5 and rGP5-FljB proteins. The fused His-rGP5 (a) and rGP5-FljB (b) were purified via Ni-NTA affinity
columns. Lanes: M, molecular weight markers; 1 and 2, purified His-rGP5 or rGP5-FljB proteins
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To monitor the longevity of the GP5-specific serum
IgG, immunized animals were bled at 12-day inter-
vals for 36 days after the third immunization and
serum IgG levels were determined by indirect ELISA.
The ELISA plates were coated with GST-tagged GP5
antigen. We analyzed the time course of the levels
of GP5-specific antibodies induced by rGP5 alone,
rGP5-FljB, or rGP5 + R848 (Fig. 8). The IgG titer in
the rGP5-FljB group reached its peak (11,520) on
day 12 post-third immunization, and then gradually
fell. The rGP5-FljB immunization induced an approxi-
mately 7–12 fold increase in the GP5-specific IgG ti-
ters compared with the rGP5 alone immunization over
the different tested time points, and the IgG titer of
the rGP5-FljB group was still significantly higher than
that of the rGP5 alone group on day 36 post-third
immunization. These results suggest that rGP5-FljB
immunization produces both a higher and longer-
lasting anti-GP5 IgG titer than immunization with
rGP5 alone.Fig. 4 Western blotting analysis of His-rGP5 and rGP5-FljB proteins. (a)
antibody. Lanes: M, molecular weight markers; 1, 1 × SDS-loading buffe
(b) Analysis of rGP5-FljB with an anti-FljB polyclonal antibody. Lanes: M
(pCold-rGP5-FljB) induced by IPTG; 2, Inclusion bodies of BL21(DE3)(pC
induced by IPTGDiscussion
PRRSV infection has been recognized as a severe threat
to the pig industry. A hallmark of the swine antibody re-
sponse against PRRSV is the abundant nonneutralizing
antibodies detected early in infection followed by a low
neutralizing antibody titer that appears at least 3 weeks
after infection [15, 16]. The viral glycoprotein can induce
a potent humoral immune response, and the production
of anti-GP5 antibody is associated with the disappear-
ance of viremia [4].
The Escherichia coli (E. coli)-based prokaryotic expres-
sion system is a powerful host cell system for expressing
heterologous genes [17]. Many glycoproteins from cells
or viruses produced in this system have shown biological
activities [18, 19]. Therefore, we aimed to express a
truncated rGP5 gene [5] without the signal peptide se-
quence and transmembrane regions in E. coli. The fused
His-rGP5 was purified via a Ni-NTA affinity column by
its His-tag (Fig. 3a). The immunoreactivity of rGP5 was
determined by western blotting, and the results show
that the heterologously-expressed protein reacts with anAnalysis of His-rGP5 and rGP5-FljB with an anti-PRRSV polyclonal
r; 2, purified His-rGP5 protein; 3, purified rGP5-FljB protein.
, molecular weight markers; 1, Lysate supernatant of BL21(DE3)
old-rGP5-FljB) induced by IPTG; 3, product of BL21(DE3)(pCold)
Fig. 5 TLR5-specific activity of recombinant fusion proteins. The
TLR5-specific activity of recombinant flagellin fusion protein was
examined on the HEK293-mTLR5 cell line expressing mouse TLR5.
Cells were treated with endotoxin-free recombinant proteins rGP5 or
rGP5-FljB at the concentration of 10 and 100 ng/ml for 5 h. For
positive controls, HEK293-mTLR5 cells were treated with the TLR5
agonist Flagellin. Supernatants were collected and expression levels
of IL-8 were then evaluated by ELISA. Error bars indicate standard
deviations of the means. Statistical significance was determined at
p < 0.01 (**) or p < 0.001 (***)
Fig. 7 PRRSV-specific IgG antibody titers in serum at day 12 after the
third immunization. C3H/HeJ mice were randomly divided into five
groups (6 mice per group) and immunized intraperitoneally either
with rGP5, rGP5-FljB, rGP5 + R848, rGP5 + aluminium adjuvant, or
PBS, respectively. These mice were immunized three times on days
0, 14, and 28 at a dose of 50 μg rGP5, 50 μg rGP5-FljB, 10 μg R848
or isochoric aluminium adjuvant in 200 μL. Blood was collected from
eye sockets on days 40 for analysis of anti-PRRSV IgG titers by ELISA.
Data reflects the mean ± SD by using the Student t test at p < 0.01
(**) or p < 0.001 (***)
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the recombinant protein retained the biological activity
of the wild-type protein.
TLRs recognize distinctive ligands, play key roles in
innate immunity, and can contribute to the development
of appropriate adaptive immune responses [20]. Recently,
several TLR ligands have been widely studied as adjuvants
for immunotherapy and vaccination [8, 21]. Among theFig. 6 Immunization schedule and GP5-specific IgG antibody titers in serum. (a) C3H/HeJ mice were randomly divided into five groups (6 mice
per group) and immunized intraperitoneally either with rGP5, rGP5-FljB, rGP5 + R848, rGP5 + aluminium adjuvant, or PBS, respectively. These mice
were immunized three times on days 0, 14, and 28 at a dose of 50 μg rGP5, 50 μg rGP5-FljB, 10 μg R848 or isochoric aluminium adjuvant in
200 μL. Blood was collected from eye sockets on days 26, 40, 52 and 64 for analysis of anti-GP5 IgG titers by ELISA. (b) GP5-specific IgG antibody
titers in serum at day 12 after the boost and third immunization. (c) IgG1 and IgG2a levels in serum at day 12 after the third immunization. Data
reflects the mean ± SD by using the Student t test at p < 0.05 (*), p < 0.01 (**) or p < 0.001 (***)
Fig. 8 The longevity of GP5-specific serum IgG titers. Mice were bled
for 36 days at 12 days intervals after 3rd immunization, and serum
IgG levels were determined by indirect ELISA. The ELISA plates were
coated with GST-taged GP5 antigen. The time course of GP5-specific
antibodies induced by rGP5 alone, rGP5-FljB or rGP5 + R848 was
analyzed. Data reflects the mean ± SD by using the Student t test at
p < 0.05 (*), p < 0.01 (**) or p < 0.001 (***)
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defined genetic codes [22]. To investigate the adjuvant ac-
tivity of fusion protein rGP5-FljB, phase II flagellin fljB
was amplified from the S. Typhimurium SL7207 strain
and the recombinant plasmid pCold-rGP5-fljB was con-
structed. The fusion protein preparation had a high degree
of purity, as only one protein band was observed (Fig. 3b).
Flagellins from Gram-negative bacteria undergo a direct
interaction with the leucine-rich regions in TLR-5 and
activate a range of inflammatory cells via a TLR-5-
dependent signaling pathway [11, 12]. We conducted a
TLR-5-specific bioactivity assay and the results showed
that stimulation with fusion protein rGP5-FljB induced a
significantly higher expression of IL-8 than stimulation
with rGP5 alone, at several different protein concentra-
tions (Fig. 5), indicating that the innate immune response
was activated by flagellin FljB.
Recently, an ever increasing number of studies have
described the adjuvant property of flagellin in the con-
text of a broad range of recombinant vaccines [23, 24].
We tested the ability of rGP5-FljB to act as an adjuvant
by administering the fusion protein rGP5-FljB to mice,
and found that immunization with the fusion protein in-
duced a significantly-enhanced GP5-specific and PRRSV-
specific IgG response compared with immunization with
rGP5 alone (Figs. 6b and 7), indicating that the polyclonal
antibodies against rGP5 were able to react with PRRSV
and FljB is an efficacious adjuvant for the induction of
antigen-specific IgG production.
Imiquimod, a synthetic TLR-7 agonist, can expedite
the immune response against influenza virus infection
when combined with influenza vaccines [25]. In this
study, the GP5-specific IgG titer following rGP5 +
R848 co-administration was significantly upregulated
after the third immunization (Fig. 6b) and persisted foralmost 5 weeks (Fig. 8). The robust IgG1/IgG2a ratio
post-third immunization in the rGP5-FljB group, simi-
lar to that of the rGP5 + R848/Alum co-administration
groups, indicated that a strong GP5-specific Th2 re-
sponse was induced by the fusion protein rGP5-FljB
(Fig. 6c).
The intranasal administration of other antigens in com-
bination with flagellin has been shown to significantly in-
crease the antigen-specific IgA titer, not only in the
mucosal compartment but also in the serum [10]. Add-
itionally, previous studies found that immunization via the
intranasal but not the subcutaneous route elicited sporo-
zoite neutralizing antibodies capable of inhibiting > 90 %
of sporozoite invasion [26]. These findings suggest that a
comparison of different administration routes of flagellin
is needed in future studies.
Conclusions
We designed a truncated rGP5 gene and prepared His-
rGP5, GST-rGP5, and rGP5-FljB proteins with a pro-
karyotic expression system. The immunoreactivites of
His-rGP5 and fusion protein rGP5-FljB were confirmed
by western blotting. After the removal of endotoxin in our
rGP5 and rGP5-FljB preparations, we verified the activa-
tion of an innate immune response via a TLR-5-specific
bioactivity assay and investigated the adjuvant activity of
FljB via administration of rGP5-FljB protein to mice. Our
findings confirm that FljB could serve as an excellent
immunoadjuvant for the production of GP5-specific and
PRRSV-specific IgG antibodies and the induction of a ro-
bust humoral immune response.
Methods
cDNA amplification
Viral RNA was extracted from the Chinese isolate HH08
of PRRSV using TRIzol reagent (Invitrogen, CA, USA),
and viral cDNA was synthesized using Oligo dT primers
(Takara, Dalian, China) according to the manufacturer’s
instructions. Based on the GP5 sequence of PRRSV
(GenBank Accession number: GQ184821), primers were
designed for amplifying a fragment covering the ORF5
gene of PRRSV (Table 1). PCR was carried out using
PrimeSTAR HS DNA Polymerase (Takara) in a 50-μl
reaction volume consisting of 1× PrimeSTAR Buffer
(Mg2+ plus), 200 μM of each dNTP, 0.2 μM of forward
and reverse primers, 1.25 U of PrimeSTAR HS DNA
Polymerase, and ~200 ng of viral cDNA template. PCR
amplifications were performed as follows: 1 cycle of
98 °C for 5 min, then 25 cycles of 98 °C for 10 s, 60 °C
for 15 s, and 72 °C for 90 s, followed by 1 cycle of 72 °C
for 10 min. The amplified PCR product was purified,
cloned into pCR2.1-T with a TA Cloning Kit (Invitrogen)
according to the manufacturer’s instructions, and se-
quenced by GenScript (Nanjing, China).
Table 1 PCR primers used in this study
Primer name Primer sequence (5′→ 3′) Application
GP5-ORF F ACTTAAGCTTGGTACCATGG Amplification of GP5 ORF
GP5-ORF R CGCTAGAGCGCTGGCAAGTG Amplification of GP5 ORF
GP5a F CCGGGATCCAACGCCAGCGACAACAAC Amplification of GP5a fragment
GP5a R CACCGCCGCTTCCACCGCCACCCTCCACTGCCCAGTCAAA Amplification of GP5a fragment
GP5b F GTGGAAGCGGCGGTGGCGGAAGCTGCATGTCCTGGCGCTA Amplification of GP5b fragment
GP5b R CCGGAATTCGAGACGACCCCATAGTTCCGCT Amplification of GP5b fragment
fljB F GGGGGAATTCGGTGGCGGTGGTTCTATGGCACAAGTAATCAACACTAACAGT Amplification of fljB fragment
fljB R GCGTCGACTTAACGTAACAGAGACAGC Amplification of fljB fragment
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The GP5 ectodomain with the deletion of its signal
peptide and transmembrane regions was designated ac-
cording to a previously published protocol with minor
modifications [5]. The truncated rGP5 was amplified
by overlap-PCR with two pairs of primers (Table 1).
BamHI and EcoRI restriction enzyme sites were intro-
duced in GP5a-F and GP5b-R, respectively (underlined
parts). A linker sequence encoding two repeated amino
acid sequences (GGGGS) was introduced into primers
GP5a-R and GP5b-F (linker sequence in black bold).
GP5a and GP5b fragments were amplified by PCR
using GP5a-F/GP5a-R and GP5b-F/GP5b-R, respect-
ively, as described above except with an extension for
30 s at 72 °C. The resulting PCR products were electro-
phoresed on 1 % agarose gels and purified as the tem-
plate of the truncated rGP5 gene amplification using
primers GP5a-F and GP5b-R. The rGP5 fragment was
inserted into the BamHI and EcoRI-digested expression
vector pColdI or pGEX-6p-1 to create pCold-rGP5 or
pGEX-6p-1-rGP5, respectively. The phase II flagellin fljB
gene was amplified from the genomic DNA of attenuated
Salmonella Typhimurium SL7207 strain using primers
fljB-F and fljB-R (Table 1). The purified PCR product was
digested and cloned into the EcoRI and SalI sites of
pCold-rGP5, resulting in a recombinant plasmid pCold-
rGP5-fljB (Fig. 1). The sequences of the resulting con-
structs were confirmed by DNA sequencing.
Expression and purification of PRRSV rGP5 and rGP5-FljB
Recombinant plasmids pCold-rGP5, pGEX-6p-1-rGP5,
and pCold-rGP5-fljB were purified with plasmid purifica-
tion kits (Takara) according to the manufacturer’s instruc-
tions and transformed into host cells, E. coli, BL21(DE3)
pLysS. Protein expression was optimized according to a
recently published method with minor modifications [18].
Briefly, the E. coli harboring pCold-rGP5, pGEX-6p-1-
rGP5, or pCold-rGP5-fljB were cultured in LB liquid
medium at 37 °C with shaking until the optical density
(OD) of the culture at 600 nm reached 0.6. Then,
isopropyl-β-d-thiogalactoside (IPTG) was added to a finalconcentration of 0.5 mM to induce expression at 25 °C for
5 h (pGEX-6p-1-rGP5) or at 15 °C for 24 h (pCold-rGP5
and pCold-rGP5-fljB). The empty vector-transformed
bacteria were used as a control. The bacteria were pel-
leted by centrifugation at 10,000 rpm, at 4 °C for
10 min and re-suspended in TE buffer (50 mM Tris
and 1 mM EDTA, pH 8.0). Next, they were digested
with lysozyme at a final concentration of 100 μg/L at
room temperature for 30 min. The cell suspension was
sonicated on ice for 30 min. Then, the lysate was
centrifuged at 10,000 rpm for 10 min at 4 °C. The
supernatant and the pellets were each mixed with
sodium dodecyl sulfate (SDS)-loading buffer. Both
samples were subjected to 12 % SDS-polyacrylamide
gel electrophoresis (SDS-PAGE). The purification of
rGP5-FljB was performed by using a His•Bind Purification
Kit (Novagen, USA) according to the manufacturer’s in-
structions, and His-rGP5 inclusion bodies were conducted
under the condition of 6 M urea. The purified proteins of
interest were designated as His-rGP5 or rGP5-FljB. The
protein contents were determined with a Bradford assay
and by SDS-PAGE analyses.
Western blotting
The antisera against PRRSV or FljB were generated by
immunizing mice with the inactivated PRRSV strain
HH08 or FljB protein mixed with Freund's adjuvant. The
purified recombinant proteins of rGP5 and rGP5-FljB
were both subjected to SDS-PAGE and then transferred
to a nitrocellulose membrane. The membranes were
blocked with blocking buffer (5 % non-fat dry milk and
0.05 % Tween-20 in phosphate-buffered saline, PBST) at
4 °C overnight. The next day, the membranes were incu-
bated with a polyclonal antibody against PRRSV or FljB
(1:1000 diluted in PBST) at 37 °C for 2 h. After washing
three times with PBST, the membranes were incubated
with a horseradish peroxidase (HRP)-conjugated second-
ary antibody (1:5000 diluted in PBST, Boster, China) at
37 °C for 1 h. The protein bands were visualized via a
diaminobenzidine enzyme-based color development in
the dark that was terminated by distilled water.
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Contaminating lipopolysaccharide (LPS) was removed from
the recombinant proteins His-rGP5 and rGP5-FljB by using
the ProteoSpin™ Endotoxin Removal Kit Maxi for protein
& peptides (Norgen, Canada) according to the manufac-
turer’s instructions, and the residual LPS content of the
protein was measured using a chromogenic end-point
tachypleus amebocyte lysate (CE TAL) assay kit (Chinese
Horseshoe Crab Reagent Manufactory Co., Ltd., Xiamen,
China) according to the manufacturer’s instructions.
TLR-5-specific bioactivity assay
The detection of IL-8 expression levels in a HEK293-
mTLR5 cell line (a gift from Dr. Yi Li, Baylor College of
Medicine, Houston, USA) was used to test for the TLR-
5-specific activity of the fusion protein rGP5-FljB.
Briefly, HEK293-mTLR5 cells were cultured in 96-well
microtiter plates (Corning, USA) at a seeding density of
5 × 104 cells in 100 μl/well of DMEM medium supple-
mented with 10 % fetal calf serum and antibiotics. The
next day, cells were treated with endotoxin-free recom-
binant proteins rGP5 or rGP5-FljB at concentrations of
10 and 100 ng/ml for 5 h. For positive controls,
HEK293-mTLR5 cells were treated with the TLR-5
agonist flagellin (Sigma-Aldrich, USA). Supernatants
were collected and expression levels of IL-8 were then
evaluated using Human IL-8 Ready-SET-Go!® ELISA Set
(eBioscience, San Diego, CA, USA).
Mouse immunization
Six-week-old female C3H/HeJ mice were purchased from
the Biomedical Research Institute of Nanjing University.
They were housed in isolators and fed a pathogen-free diet
and water. The procedures described in this study were
approved by the Committee on the Ethics of Animal
Experiments of Yangzhou University, Yangzhou, China.
To test whether vaccination with the fusion protein
rGP5-FljB provides a greater immune response than
vaccination with rGP5 alone or with other adjuvants,
C3H/HeJ mice were randomly divided into five groups
(6 mice per group) and immunized intraperitoneally either
with rGP5, rGP5-FljB, rGP5 + R848 (Imidazoquinoline;
Enzo Life Sciences, USA), rGP5 + aluminum adjuvant
(Alum, Thermo, USA), or PBS. These mice were immu-
nized three times on days 0, 14, and 28 at doses of 50 μg
rGP5, 50 μg rGP5-FljB, 10 μg R848 or isochoric aluminum
adjuvant in 200 μL. Blood was collected from eye sockets
on days 26, 40, 52, and 64 (Fig. 6a) and the sera were
stored at—70 °C until they were tested by ELISA to deter-
mine their antibody levels.
Detection of anti-GP5 and anti-PRRSV antibodies
Serum IgG, IgG1, and IgG2a titers against GP5 or IgG
titers against PRRSV were measured by ELISA accordingto a previously described protocol with minor modifica-
tions [27]. Briefly, 96-well microtiter plates were coated
with recombinant GST-GP5 (0.2 μg/ml) or purified inac-
tivated PRRSV strain HH08 (0.5 μg/ml) in 50 mM car-
bonate buffer (pH 9.6) at 4 °C overnight and blocked for
2 h at 37 °C with blocking buffer (1 % bovine serum al-
bumin in PBST). After washing three times with PBST,
sera were added at an initial dilution of 1:100 with a
two-fold dilution series in blocking buffer and incubated
for 2 h at 37 °C. After five washes with PBST, antigen-
specific antibodies were detected using goat anti-mouse
IgG conjugated to HRP (1:10,000 dilution) or goat anti-
mouse IgG1 and IgG2a conjugated to HRP (1:3000 dilu-
tion) for 1 h at 37 °C. The ELISAs were developed using
3,3≠,5,5 ≠ -Tetramethylbenzidine and H2O2 as sub-
strates, and the ODs were read at 450 nm (A450) with
an ELISA reader (Bio-Tek EL 680, USA).
Statistical analysis
The significance of the difference between groups of fused
or mixed proteins and rGP5 alone was determined by a
Student’s t-test with Instat version 5.0 (GraphPad Soft-
ware, San Diego, CA). Statistical significance was deter-
mined at p < 0.05 (*), p < 0.01 (**) or p < 0.001 (***).
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